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Study Objectives. To evaluate the dose and frequency of insulin detemir for
patients with diabetes mellitus undergoing conversion from insulin glar-
gine to insulin detemir, and to assess glycemic control, weight gain, and
risk of hypoglycemia after converting to insulin detemir.
Design. Retrospective medical record review.
Setting. Large academic medical center.
Patients. Thirty-one patients with type 1 (10 patients) or type 2 (21 patients)
diabetes who were converted from insulin glargine to insulin detemir by
usual practice between January 1, 2006, and March 3, 2007, after an Iowa
Medicaid formulary switch.
Measurement and Main Results.Data were collected for 12 months after
conversion from insulin glargine to insulin detemir. No significant change
in mean basal insulin dose was noted in patients with type 1 diabetes at
the end of 12 months (insulin detemir 31.1 units/day vs baseline insulin
glargine 32.0 units/day, p=0.89; insulin detemir 0.41 unit/kg/day vs base-
line insulin glargine 0.42 unit/kg/day, p=0.91). In patients with type 2 dia-
betes, however, the mean basal insulin dose was significantly higher with
insulin detemir compared with baseline insulin glargine (74.2 vs 55.8
units/day, p=0.002; 0.68 vs 0.48 unit/kg/day, p=0.001) at the end of
12 months. Twice-daily administration was required in a higher propor-
tion of patients receiving insulin detemir (15 patients [48%]) at
12 months compared with insulin glargine (4 patients [13%]) at baseline
(p=0.043). A significant change in hemoglobin A1c was not observed in
patients with type 1 diabetes (9.7% with insulin detemir vs 9.3% with
insulin glargine, p=0.41) or type 2 diabetes (9.4% with insulin detemir vs
9.7% with insulin glargine at baseline, p=0.57) despite the use of higher
insulin detemir doses in patients with type 2 diabetes. No significant
differences in weight or frequency of hypoglycemia were noted.
Conclusion. Treatment with insulin detemir appears to require more fre-
quent administration and higher insulin doses compared with insulin glar-
gine in patients with type 2 diabetes, with 33% higher doses, on average,
observed in this study. These findings suggest that a unit-for-unit conver-
sion from insulin glargine to insulin detemir, as suggested by the manufac-
turer of insulin detemir, may not be adequate in patients with type 2
diabetes.
Key Words: glargine, detemir, basal insulin, long-acting insulin, insulin
dose conversion.
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Several landmark clinical trials have demon-
strated that tight glycemic control reduces the inci-
dence and delays the progression of long-term
complications, particularly microvascular compli-
cations, associated with diabetes mellitus.1–4
Guidelines from the American Diabetes Associa-
tion recommend targeting a hemoglobin A1c (A1C)
level of less than 7%.5 Long-acting insulin, with or
without bolus insulin, is often required to achieve
this tight glycemic control. There are two long-act-
ing insulins available: insulin glargine (Lantus; Sa-
nofi-Aventis, Bridgewater, NJ) and insulin detemir
(Levemir; Novo Nordisk, Princeton, NJ). Both of
these insulins have a long duration of action and
have little variability in effect throughout the dos-
ing interval (Table 1). However, insulin detemir
has a dose-dependent onset and duration of action.
Unlike insulin glargine, insulin detemir has a neu-
tral pH and does not precipitate on injection. It
instead exhibits its prolonged duration of action as
a result of strong self-association and reversible
binding to albumin. On May 1, 2006, Iowa Medic-
aid switched its preferred long-acting insulin from
insulin glargine to insulin detemir, requiring the
majority of insulin-dependent patients with Medic-
aid in Iowa to be switched to insulin detemir. The
reason for the formulary change was unclear.
The manufacturer of insulin detemir suggests
using a unit-for-unit dose conversion when
switching patients from insulin glargine to insu-
lin detemir.8 Previous published studies, how-
ever, have evaluated the appropriateness of this
dosage conversion primarily as a secondary end
point or in trials of short duration.12–17 Thus,
the primary objective of this study was to evalu-
ate the dose and frequency of insulin detemir
required when converting patients with type 1
diabetes mellitus (T1DM) or type 2 diabetes
mellitus (T2DM) from insulin glargine to insulin
detemir. Secondary objectives were to assess gly-
cemic control, weight gain, and the risk of hypo-
glycemia after conversion to insulin detemir.
Methods
This retrospective analysis evaluated 31
patients who underwent conversion from insulin
glargine to insulin detemir by usual practice at a
large academic medical center between January
1, 2006, and March 3, 2007. Patients were
included if they were at least 18 years of age
and had T1DM or T2DM and were excluded if
they had gestational diabetes mellitus. Electronic
medical records were used to identify patients,
and data were collected during the 3 months
before and 12 months after insulin conversion.
This study was approved by the University of
Iowa Institutional Review Board.
Primary outcome measures were mean basal
insulin doses in both units/day and units/kg/day
on the index date, defined as the date of conver-
sion from insulin glargine to insulin detemir, and
at 12 months; mean total insulin doses (basal
plus bolus) in patients receiving more than one
type of insulin; and frequency of basal insulin
administration (once/day vs twice/day). Secondary
outcomes were change in A1C and body weight
observed during the 12 months after insulin con-
version. In addition, the frequency of hypoglyce-
mia, defined as the proportion of patients
reporting at least one episode of hypoglycemia,
was assessed during the 3 months before the
index date while receiving insulin glargine and
compared with the first 3 months after conver-
sion to insulin detemir using any episode noted
within the electronic medical records.
Statistical analysis was performed using the
SPSS software, version 17 (Chicago, IL). Paired t
tests were used for continuous variables, includ-
ing insulin dose, A1C, and weight. Discrete vari-
ables were analyzed with v2 statistics. The
analysis was performed using the last value car-
ried forward for patients who did not complete
the full 12 months of insulin detemir therapy. A
planned subgroup analysis was performed to
assess for differences between patients with
T1DM and those with T2DM.
Results
A total of 31 patients, 10 patients with T1DM
(32.3%) and 21 patients with T2DM (67.7%),
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were included in the analysis; their baseline
characteristics are shown in Table 2. The aver-
age age was 45 years, and patients generally had
poorly controlled diabetes, with a mean baseline
A1C of 9.6%. The primary reason that patients
were converted from insulin glargine to insulin
detemir was insurance requirements, and the
majority of patients were covered by Iowa Med-
icaid. Two patients had private insurance: one
patient was converted to insulin detemir in an
effort to reduce blood glucose variability and
occurrence of hypoglycemia, whereas the other
patient was converted due to the inability to mix
insulin glargine with the patient’s bolus insulin.
(Although this was the reason documented in
the patient’s medical records, it should be noted
that the manufacturer of insulin detemir does
not recommend mixing insulin detemir with any
other insulin preparations.)
Seven patients discontinued insulin detemir
before completing 12 months of therapy. Four
of these patients discontinued insulin detemir as
a result of a lack of improvement in or worse
blood glucose levels after a 4–7-month trial. Of
the other three patients, one had an allergic
reaction to insulin detemir, one was started on
an insulin pump, and one discontinued insulin
after subsequently developing hyperkalemia.
The majority (23 patients [74%]) were con-
verted from insulin glargine to insulin detemir
on a unit-for-unit basis. Of the eight patients
who were not converted on a unit-for-unit basis,
five were placed on a higher insulin dose, poten-
tially due to uncontrolled diabetes, and three had
a decrease in insulin dose on conversion. Twelve
months after switching, no significant change in
mean insulin detemir dose was noted compared
with baseline insulin glargine dose in patients
with T1DM (31.1 vs 32.0 units/day, p=0.89;
0.41 vs 0.42 unit/kg/day, p=0.91; Table 3). Con-
versely, patients with T2DM required a higher
mean insulin detemir dose compared with the
baseline insulin glargine dose (74.2 vs
55.8 units/day, p=0.002; 0.68 vs 0.48 unit/kg/
day, p=0.001). Insulin detemir doses were
recorded at baseline (dose started on conversion)
and at 1, 3, 6, 9, and 12 months after conversion
(Table 4). At 1 month, patients with T2DM were
on 11% higher mean basal insulin doses; at
3 months, 15% higher doses; at 6 months, 27%
higher doses; at 9 months, 30% higher doses;
and by the end of 12 months, patients were
maintained on 33% higher insulin detemir doses
compared with insulin glargine. Three patients
with T2DM had bolus insulin added to their dia-
betes regimen at the end of the study period
compared with baseline (67% vs 52%, p=0.35).
Lifestyle modifications and changes in other
drug therapy were documented to assess whether
Table 2. Baseline Characteristics of the 31 Study
Patientsa
Characteristic Value
Female sex 19 (61.3)
Diabetes mellitus type
Type 1 10 (32.3)
Type 2 21 (67.7)
Age (yrs) 45  27
Type 1 diabetes 35  11
Type 2 diabetes 50  10
Duration of diabetes
2–4 yrs 2 (6.5)
5–10 yrs 9 (29.0)
> 10 yrs 20 (64.5)
Mean baseline A1C (%) 9.58  2.45
Type 1 diabetes 9.29  2.89
Type 2 diabetes 9.72  2.27
At goal < 7% 4 (12.9)
Mean baseline weight (kg) 100.6  30.6
Type 1 diabetes 76.1  17.9
Type 2 diabetes 112.3  28.6
Reason for conversion
Insurance 29 (93.5)
Other 2 (6.5%)
Data are no. (%) of patients or mean  SD.
aOf the 31 patients, 10 had type 1 and 21 had type 2 diabetes.
Table 1. Comparison of Long-Acting Insulin Preparations
Property Insulin Glargine6, 7 Insulin Detemir7–10
Onset 1.1 hrs 1.1–2 hrs (dose dependent)
Duration 10.8–>24 7.6–>24 hrs (dose dependent)
Peak No significant peak No significant peak
Insulin pH 4.0 (acidic) 7.4 (neutral)
Mechanism of prolonged
duration of action
Low aqueous solubility
at physiologic pH results
in precipitation on injection
Strong self-association of the
drug molecules and reversible
binding to albumin
Recommended starting dose 10 units once/day 0.1–0.2 units/kg once/day or
10 units once or twice/day
Cost11 $118.99/10-ml vial $135.99/10-ml vial
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changes in these factors could account for any
change in insulin doses or glycemic control
observed (Table 5). A similar number of patients
were found to be implementing lifestyle modifica-
tions at baseline and study completion, as were a
similar number of patients taking oral drugs.
Thus, these changes were thought to have mini-
mal impact on glycemic control and on the
increases in insulin detemir doses observed in this
study.
Fifteen patients with T1DM or T2DM were
administering insulin detemir twice/day at the
end of 12 months compared with four patients
administering insulin glargine at baseline (48%
vs 13%, p=0.043; Table 6). The percentages of
patients receiving twice-daily basal insulin
administration were similar at study completion
in patients with T1DM and T2DM (50% and
48%, respectively). Seven (47%) of the 15
patients who were taking twice-daily basal insu-
lin at the end of the study period were automati-
cally converted from once-daily to twice-daily
administration on conversion to insulin detemir
on the index date. This may have been due to
Table 3. Mean Basal and Total Insulin Doses at Baseline and at Study Conclusion for Patients with Type 1 or Type 2 Dia-
betes Mellitus
Primary End Point
Type of
Diabetes
Mellitusa
Insulin
Glargine
(baseline)
Insulin
Detemir
(12 mo)
Change in
Insulin
Dose p Value
Mean basal insulin dose (units/day) Type 1 32.0 31.1 0.9 0.89
Type 2 55.8 74.2 18.4 0.002
Mean basal insulin dose (units/kg/day) Type 1 0.42 0.41 0.01 0.91
Type 2 0.48 0.68 0.20 0.001
Mean total insulin doseb (units/day) Type 1 53.9 54.7 0.80 0.92
Type 2 84.0 106.8 22.8 0.001
Mean total insulin doseb (units/kg/day) Type 1 0.69 0.69 0 0.95
Type 2 0.75 0.97 0.22 0.002
aOf the 31 patients, 10 had type 1 and 21 had type 2 diabetes.
bTotal insulin dose includes both basal and bolus insulin doses.
Table 4. Mean Basal Insulin Doses over Time in Patients with Type 1 or Type 2 Diabetes Mellitus
Insulin Dose
Type of
Diabetes
Mellitus
Insulin
Glargine
(baseline)
Insulin Detemir
Baseline 1 Months 3 Months 6 Months 9 Months 12 Months
Mean basal insulin dose
(units/day)
Type 1 32.0 33.8 33.2 30.2 35.3 32.4 31.1
Type 2 55.8 54.8 62.2 63.9 70.8 72.8 74.2
Mean basal insulin dose
(units/kg/day)
Type 1 0.42 0.43 0.42 0.39 0.45 0.42 0.41
Type 2 0.48 0.49 0.56 0.57 0.64 0.66 0.68
Table 5. Lifestyle Changes or Changes in Other Antidia-
betic Drugs in the 31 Study Patients
Type of Change in
Diabetes Regimen
Insulin
Glargine
(baseline)
Insulin
Detemir
(12 mo)
Lifestyle modifications 12 (38.7) 13 (41.9)
No. of concomitant oral
antidiabetic drugs
0 17 (54.8) 18 (58.1)
1 7 (22.6) 10 (32.3)
2 6 (19.4) 3 (9.7)
3 1 (3.2) 0 (0)
Patients taking
concomitant
oral drugs
14 (45.2) 13 (41.9)
Insulin type
Basal insulin only 10 (32.3) 7 (22.6)
Basal + bolus insulin 21 (67.7) 24 (77.4)
Data are no. (%) of patients.
Table 6. Percentage of Patients Administering Basal Insu-
lin Twice/Daya
Insulin Type
Patients with
Type 1
Diabetes
Mellitus
(n=10)
Patients with
Type 2
Diabetes
Mellitus
(n=21)
All Patients
(n=31)
Insulin glargine
(baseline)
0% 19% 13%b
Insulin detemir
(index datec)
40% 33% 35%
Insulin detemir
(12 mo)
50% 48% 48%b
aThe frequency of dosing was twice/day except for one patient who
received insulin detemir 3 times/day at 12 mo.
bp=0.043 for the percentage of patients receiving insulin glargine
at baseline compared with those receiving insulin detemir at
12 mo.
cThe index date was defined as the date of conversion from insulin
glargine to insulin detemir.
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physician knowledge of the potentially shorter
duration of action, which has been demonstrated
to be dose dependent in previous studies.10 The
mean daily insulin detemir dose was 0.53 unit/
kg at the time that these seven patients were
automatically converted from once-daily insulin
glargine to twice-daily insulin detemir (insulin
detemir dose on the index date).
A nonsignificant increase in A1C was
observed in patients with T1DM from baseline
to study completion (9.3% vs 9.7%, p=0.41),
with no change in basal insulin dose in these
patients. Despite the use of significantly higher
insulin detemir doses in patients with T2DM, no
significant change in A1C was observed from
baseline to study completion (9.7% vs 9.4%,
p=0.57). In addition, with the conversion, a
lower proportion of patients achieved a goal
A1C of less than 7% as recommended by the
American Diabetes Association at the end of the
12 months, although this was a nonsignificant
difference (13% vs 4%, p=0.148). Weight gain
was not observed despite an increase in total
insulin doses (mean change 1.4 kg, p=0.87).
Mean weight change was 0.4 kg in patients
with T1DM and 1.82 kg in patients with
T2DM from baseline to study completion. The
number of patients experiencing at least one epi-
sode of hypoglycemia did not differ significantly
between insulin glargine and insulin detemir (13
patients [41.9%] vs 6 patients [19.4%],
p=0.054).
Discussion
In this study, treatment with insulin detemir
required higher basal insulin doses compared
with insulin glargine, with 33% higher doses
observed in patients with T2DM 12 months after
conversion. Most of the patients in this study
had uncontrolled diabetes, with an average A1C
of 9.6% at baseline. Thus, it is not unexpected
that the patients would require higher insulin
doses to reach glycemic targets. However, con-
trary to what one would expect, the higher
doses did not result in improved glycemic con-
trol. It could be argued that a clinically signifi-
cant change in A1C was observed in patients
with T2DM (although not statistically signifi-
cant), but there was one patient whose A1C
decreased from 16.2% at baseline while receiving
glargine to 9.8% while receiving determir, and
this very dramatic change in A1C skewed the
data. When the data for this patient were
removed, the A1C did not change from baseline
(mean 9.4%). These findings suggest that a unit-
for-unit conversion from insulin glargine to
insulin detemir, as suggested by the manufac-
turer of insulin detemir, may not be adequate.
In addition to an increase in basal insulin doses,
an increase in total insulin doses was also
observed. The reason for the lack of improve-
ment in A1C despite more aggressive insulin
regimens is unclear.
The need for twice-daily administration was
found to be more frequent with insulin detemir
than with insulin glargine. This can be explained
by the pharmacokinetic differences between insu-
lin detemir and insulin glargine; insulin glargine
typically has a 24-hour duration of action,
whereas the duration of action of insulin detemir
is dose dependent. In one study, insulin detemir’s
duration of action was demonstrated to vary from
5.7, 12.1, 19.9, 22.7, and 23.2 hours with doses
of 0.1, 0.2, 0.4, 0.8, and 1.6 units/kg, respec-
tively.10 In our study, the average insulin detemir
dose at 12 months was 0.41 unit/kg/day in
patients with T1DM (10 patients) and 0.68 unit/
kg/day in patients with T2DM (21 patients).
Thus, it would be expected to have durations
around 20 and 21 hours, respectively. The aver-
age basal insulin dose in patients who were
receiving twice-daily insulin detemir at study
completion was 0.40 unit/kg/day in patients with
T1DM (five patients) and 0.87 unit/kg/day in
patients with T2DM (10 patients) at 12 months.
This could help explain the increased number of
patients requiring twice-daily administration of
insulin detemir, particularly in the patients with
T1DM. This may also contribute to the increase
in basal insulin dose when patients with T2DM
were converted to insulin detemir, as it has been
demonstrated in previous trials that when twice-
daily administration of basal insulin is used, the
basal insulin dose is often elevated without corre-
sponding glycemic control.18–20 It should be con-
sidered that more frequent administration may
also result in increased health care costs and bur-
den to the patient and may not be desirable in all
patients.
In addition, no significant weight gain or
change in the frequency of hypoglycemia was
observed despite the use of higher basal insulin
doses in patients with T2DM. Although not sta-
tistically significant, it can be argued that the
differences observed were clinically significant
and may be important considerations in patients
experiencing difficulties with weight gain or
hypoglycemia while being treated with insulin
glargine.
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Previous trials have compared insulin glargine
and insulin detemir doses, primarily as a sec-
ondary end point or for a shorter study dura-
tion, and have suggested that higher insulin
detemir doses may be required compared with
insulin glargine to achieve similar or improved
glycemic control.12–14, 17 In one study, higher
mean basal insulin doses were reported for 321
patients with T1DM with twice-daily insulin det-
emir compared with once-daily insulin glargine
after 26 weeks (0.47 vs 0.35 unit/kg/day) with
similar A1C reduction (8.8% to 8.2% in the
insulin detemir group and 8.7% to 8.2% in the
insulin glargine group); however, no p value
was reported for the difference between doses.13
The minimal change in basal insulin doses in
patients with T1DM observed in this study is
different than that observed in a previous trial in
which basal insulin doses were found to increase
from 36 to 46 units/day after 12 months in 24
patients with T1DM who were converted from
insulin glargine to insulin detemir.15 This was
compared with a control group of patients who
continued to receive insulin glargine, in whom
there was no change in dose. The explanation
for the difference in findings between our study
and this previous study is unclear, but it is pos-
sible that no difference was observed in our
study because of the small number of patients
with T1DM. Although no statistically significant
change in A1C was noted in our study, it could
be argued that a clinically relevant increase in
A1C was observed after the change from insulin
glargine to insulin detemir, indicating that per-
haps higher insulin detemir doses were war-
ranted.
Two different studies in patients with T2DM
reported a similar increase in mean basal insulin
detemir dose requirements.12, 14 Whereas one
trial found no significant difference in basal
insulin doses after 52 weeks in patients con-
verted to either insulin detemir or insulin glar-
gine (baseline A1C 8.7%),17 another study noted
an increase in mean basal insulin doses in
patients with T2DM from 0.27 to 0.32 unit/kg/
day (p<0.001) when patients were converted
from once-daily insulin glargine to once- or
twice-daily insulin detemir, with a subsequent
decrease in A1C (0.59%, p<0.0001) after
12 weeks (baseline A1C 8.31%).12 Most of the
patients (79%) in this trial were converted to
once-daily insulin detemir. Another study ran-
domized patients to either once-daily insulin
glargine (248 patients) or once-daily (45%) or
twice-daily (55%) insulin detemir (227 patients)
and found higher daily insulin detemir doses of
0.78 unit/kg (0.52 unit/kg with once-daily insu-
lin detemir and 1.00 unit/kg with twice-daily
insulin detemir) compared with 0.44 unit/kg
with insulin glargine, with similar glycemic
reductions (baseline A1C decreased from 8.6%
to 7.2% and 7.1% with insulin detemir and insu-
lin glargine, respectively).14 A pooled analysis of
22 studies of at least 20 weeks’ duration in
patients with T2DM initiating either insulin glar-
gine or insulin detemir evaluated dose require-
ments and found that a significantly higher
insulin detemir dose was needed to achieve the
same decrease in A1C (51.5 vs 38.8 units/
day).21 It should be noted that only one of the
trials included in this analysis was a head-to-
head comparison.
The difference in dose requirements between
insulin detemir and insulin glargine is further
supported by a case series assessing the reverse
scenario: basal insulin dose requirements in
three patients with T2DM who were converted
from insulin detemir to insulin glargine.16 Basal
insulin doses were found to decrease substan-
tially in all three patients, from 206 units of
insulin detemir to 104 units of insulin glargine
7 weeks after conversion in the first patient,
from 102 to 81 units after 6 weeks in the second
patient, and from 126 to 104 units after 6 weeks
in the third patient. No change or a slight
improvement in A1C was observed on conver-
sion to insulin glargine.
Conflicting recommendations regarding the
conversion between intermediate-acting and
long-acting insulin also add to the confusion.
When converting from intermediate-acting NPH
insulin to long-acting insulin detemir, the manu-
facturer states that some patients may require
more insulin detemir compared with NPH insu-
lin to achieve glycemic targets.8 This was dem-
onstrated in a study in which the insulin
detemir doses required were 1.4–4 times higher
(mean 2.4) than the NPH insulin doses.22 In
contrast, when patients are transferred from
twice-daily NPH insulin to once-daily insulin
glargine, it is recommended to reduce the initial
insulin glargine dose by 20% to reduce the risk
of hypoglycemia and then adjust the dose based
on patient response.6 Given that higher doses of
insulin detemir are generally required compared
with NPH insulin and that insulin doses should
be reduced when converting from NPH insulin
to insulin glargine, the evidence supporting a
unit-for-unit conversion from insulin glargine to
insulin detemir seems inconsistent.
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There are some study limitations that should be
noted. First, this was a retrospective analysis with
a small patient population. Second, more than
half (63.3%) of the patients included in this study
had an adjustment in their insulin glargine dose
within 3 months before their documented base-
line A1C. Thus, the baseline A1C may not have
been a true reflection of the patients’ glycemic
control while receiving insulin glargine and may
have actually overestimated their baseline A1C. In
addition, data on drug adherence were unable to
be collected given the retrospective nature of the
study. Therefore, it is possible that no improve-
ment in glycemic control was observed despite
the higher prescribed insulin detemir doses due
to poor adherence rates. Similarly, it should be
noted that diabetes is a progressive disorder and
often requires intensification of therapy the
longer a patient has the disease, and there was no
control group in this study for comparison. This,
too, could be suggested as the reason that no A1C
reduction was observed with the higher insulin
detemir doses, and the lack of a control group for
comparison limited our ability to assess for this.
However, given that patients seemed to require
higher doses even early in the follow-up period
(at 1, 3, and 6 mo), disease progression was not
thought to be the primary reason for the higher
insulin detemir doses observed in patients with
T2DM.
Conclusion
Treatment with insulin detemir appears to
require more frequent administration and higher
insulin doses compared with insulin glargine in
patients with T2DM, with 33% higher doses, on
average, observed in this study. These findings
suggest that a unit-for-unit conversion from
insulin glargine to insulin detemir as suggested
by the manufacturer of insulin detemir may not
be adequate, particularly in patients with uncon-
trolled T2DM.
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